Abstract:Background: Brain metastases (BM) represent one of the most common challenges related to non-small cell lung cancer (NSCLC), with evolving treatment strategies. We have conducted a phase II clinical trial in a Chinese population to evaluate concomitant treatment with whole brain radiotherapy (WBRT) and Gefitinib in patients with BM from NSCLC. The purpose of this study is to report the efficacy and toxicity of this treatment, and assess its impact on patient Quality of Life (QoL) and survival post-treatment.Patients and methods: Between October 2005 and January 2007, 21 patients were enrolled and received 40 Gy/20f/4w WBRT. Gefitinib was administrated orally at a dosage of 250 mg/day during the radiation course and was continued for each 28-day treatment cycle until progression of the disease, unacceptable toxicity, or withdrawal of consent. The primary end point of the study was tumor response and QoL The secondary end points were toxicity and survival. Objective response rate according to the RECIST criteria was recorded. Health-related QoL was measured using FACT-Br (V4.0) and toxicity was evaluated and recorded using the NCI Common Toxicity Criteria. The Kaplan-Meier method was used to evaluate patient survival. Univariate analysis of patient characteristics and tumor responses was conducted using the Chi-square and Fisher's exact test.Results: Four (19%) and 13 patients (62%) had a complete and partial response respectively, while 3 patients disease remained stable and I patient had progression of the disease. The overall response rate (81%, 95% confidence interval (Cl): 58-95%) exceeded the goal per study design. The median progression-free survival and overall survival were 10.0 months (95% Cl: 7.5-12.5 months)and 13.0 months (95% Cl: 8.2-17.8 months), respectively. The most frequent toxicities included rash (86%) and diarrhea (43%), with only 3 patients developing a grade III diarrhea. Other grade H or higher toxicities occurring in about 50% of patients included nausea, vomiting, headache, and fatigue. Most side effects were grade II and well tolerated by supportive care. Gender and cigarettes/year were predictive factors for the responses found in univariate analysis. All domains of QoL were significantly improved following treatment.Conclusion: Our data suggests that concomitant treatment was well tolerated, with promising activity and a significant improvement of QoL in a Chinese population with brain metastases from NSCLC. Although the data presented herewithin appears promising, more data from randomized trials are needed to further validate this regimen of WBRT/Gefitinib. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

Clinical Study of Mailgnant Brain Gliomas Treated by Interstitial Radiotherapy and Interstitial Chemotherapy

Therapeutic Effects and Quality of Life in 37 Glioma Patients with Postoperative Intensity-Modulated Radiotherapy

Impact of Microsurgery and Postoperative Radiotherapy on Neurological Function in Intramedullary Spinal Cord Gliomas

Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib in a Chinese Population.

Clinical analysis of superselective interventional chemotherapy for malignant glioma patients based on in vitro chemosensitivity assay

[Long-Term Effect of Chemotherapy Combined with Radiotherapy in Treatment of Intracranial Germinoma: Report of 39 Cases].

[Neuroimaging diagnosis and therapeutic efficacy of different surgical methods of gliomatosis cerebri]

Clinical Effect of Temozolomid Combined with Concurrent Radiotherapy on High Grade Intracranial Glioma

Ctni-05. A Prospective Study Of Tumor-Treating Fields Combined With Systemic Therapy In Recurrent Glioblastoma

The clinic follow-up on chemotherapy and radiotherapy of children intracrinial germinoma

Prognostic Evaluations of Recurrent Gliomas and Preliminary Efficacies of Combined Modality Therapy

Prospective Study of Chemo-Radiation Therapy Versus Radiation Therapy Alone in the Treatment of Diffuse Intrinsic Brain Stem Glioma

Modified Grading System for Clinical Outcome of Intracranial Non-Germinomatous Malignant Germ Cell Tumors

Radiotherapy in Different Doses for Non-Small Cell Lung Cancer Patients with Brain Metastasis-Phase Ⅰ-Ⅱ Study

Post-operative Efficacy of Chemo-Radiotherapy and Prognosis Analysis on 112 Cases of High-Grade Gliomas

Stereotactic Radiosurgery Combined with Chemotherapy for Primary Central Nervous System Lymphoma

Clinical Effect of Intensity Modulated Radiation Therapy Combined with Concomitant and Adjuvant Temozolomide in the Treatment for Malignant Glioma

A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma

Surgical treatment of gliomatosis cerebri

Clinical Study of Fractionated Stereotactic Radiotherapy in Patients with Intracranial Metastatic Tumors

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma